Press Releases

May 15, 2023
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share of profit of KORSUVA ® (difelikefalin) injection – – Acceleration in demand for KORSUVA injection as evidenced by total vial sales more than doubling quarter to quarter – – Three late-stage oral...
Read More
Feb 08, 2023
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment STAMFORD, Conn. , Feb. 08, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to...
Read More
email alerts